VIVUS, Inc. (NASDAQ:VVUS)’s share price shot up 4.1% during trading on Thursday . The stock traded as high as $0.53 and last traded at $0.51. 1,032,000 shares were traded during trading, an increase of 42% from the average session volume of 728,808 shares. The stock had previously closed at $0.49.
Separately, ValuEngine lowered VIVUS from a “buy” rating to a “hold” rating in a research note on Friday, September 1st.
The stock has a market cap of $52.24, a P/E ratio of 1.47 and a beta of 0.77. The company has a current ratio of 7.47, a quick ratio of 7.09 and a debt-to-equity ratio of 643.86.
Several institutional investors have recently made changes to their positions in VVUS. AJO LP purchased a new position in shares of VIVUS during the second quarter valued at $3,329,000. OxFORD Asset Management LLP grew its stake in VIVUS by 58.2% in the second quarter. OxFORD Asset Management LLP now owns 929,511 shares of the biopharmaceutical company’s stock valued at $1,134,000 after purchasing an additional 341,976 shares during the last quarter. Russell Investments Group Ltd. grew its stake in VIVUS by 166.2% in the third quarter. Russell Investments Group Ltd. now owns 395,527 shares of the biopharmaceutical company’s stock valued at $392,000 after purchasing an additional 246,927 shares during the last quarter. Macquarie Group Ltd. purchased a new position in VIVUS in the third quarter valued at about $192,000. Finally, Northern Trust Corp grew its stake in VIVUS by 16.8% in the second quarter. Northern Trust Corp now owns 275,097 shares of the biopharmaceutical company’s stock valued at $335,000 after purchasing an additional 39,473 shares during the last quarter. Hedge funds and other institutional investors own 31.30% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.com-unik.info/2017/12/23/vivus-vvus-shares-up-4-1.html.
VIVUS Company Profile
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
What are top analysts saying about VIVUS? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for VIVUS and related companies.